GALT
GALECTIN THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$3.89
+4.85%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +59.0%
- EBIT
- +54.1%
- EPS
- +33.3%
- Free cash flow
- +55.4%
- Operating cash flow
- +55.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +76.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- +43.4%
- EBIT
- +52.7%
- Net income
- +34.5%
- EPS
- +36.8%
- Free cash flow
- +42.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026